Aung Naing, MD, FACP @ANaingMD @MDAndersonNews #adverseevents #Cancer #Research Strategies for improving the management of immune-related adverse events

Aung Naing, MD, FACP MD Anderson speaks about Strategies for improving the management of immune-related adverse events.

You can download the IO Tox Management below -
IOS -
https://apps.apple.com/us/app/io-tox-management/id1514006592

Android -
https://play.google.com/store/apps/details?id=com.projectronin.iotoxman&hl=en_US&gl=US

You can find the full Abstract through the link below -
https://jitc.bmj.com/content/8/2/e001754.full



Instract
Durable and drastic responses in many difficult-to-treat malignancies have been observed with the advent of immunotherapeutic agents, outlining a path to overcoming cancer. Immune checkpoint inhibitors (ICPi) are a class of immunotherapy agents that, by reinvigorating the suppressed immune system, attack tumor cells. However, unbridled T-cell activity disrupts immune homeostasis and, in a large proportion of patients, causes a unique spectrum of side effects termed immune-related adverse events (irAEs). These irAEs vary from the side effects that conventional chemotherapeutic agents create. Life-threatening and fatal incidents have been recorded, but the majority of irAEs are manageable with corticosteroids and other immunosuppressive agents. Management of irAEs has been difficult for patients, clinicians, and healthcare providers alike, in the absence of predictive biomarkers to classify patients at risk for irAEs and a systematic method to diagnose, report and treat irAEs. The incidence of irAEs would inevitably increase with the growing use of ICP is for the treatment of different cancers. There is a compelling need to implement strategies, both in community settings and in cancer centers, to handle irAEs effectively. To this end, we propose several strategies in this paper, such as providing patient education, harmonizing the guidelines for irAE management, standardizing irAE reporting, improving the selection of immunosuppressive agents, conducting preclinical, clinical, and translational studies to better understand irAEs, including high-risk patients, integrating diagnostic tools to personalize irAE management.